KR20150096370A - 항불안제 조성물, 제형 및 사용방법 - Google Patents

항불안제 조성물, 제형 및 사용방법 Download PDF

Info

Publication number
KR20150096370A
KR20150096370A KR1020157007330A KR20157007330A KR20150096370A KR 20150096370 A KR20150096370 A KR 20150096370A KR 1020157007330 A KR1020157007330 A KR 1020157007330A KR 20157007330 A KR20157007330 A KR 20157007330A KR 20150096370 A KR20150096370 A KR 20150096370A
Authority
KR
South Korea
Prior art keywords
nmda receptor
receptor antagonist
anxiety
administered
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157007330A
Other languages
English (en)
Korean (ko)
Inventor
스튜어트 엘. 웨그
Original Assignee
스튜어트 엘. 웨그
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스튜어트 엘. 웨그 filed Critical 스튜어트 엘. 웨그
Publication of KR20150096370A publication Critical patent/KR20150096370A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020157007330A 2012-08-23 2013-08-23 항불안제 조성물, 제형 및 사용방법 Withdrawn KR20150096370A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261692380P 2012-08-23 2012-08-23
US61/692,380 2012-08-23
PCT/US2013/056424 WO2014031975A1 (en) 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use

Publications (1)

Publication Number Publication Date
KR20150096370A true KR20150096370A (ko) 2015-08-24

Family

ID=50148531

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157007330A Withdrawn KR20150096370A (ko) 2012-08-23 2013-08-23 항불안제 조성물, 제형 및 사용방법

Country Status (11)

Country Link
US (4) US20140057988A1 (enExample)
EP (2) EP2887930A4 (enExample)
JP (2) JP6722453B2 (enExample)
KR (1) KR20150096370A (enExample)
CN (1) CN104902883A (enExample)
AU (1) AU2013305580A1 (enExample)
BR (1) BR112015003796A2 (enExample)
IL (1) IL237340A0 (enExample)
MX (1) MX2015002378A (enExample)
SG (1) SG11201501292UA (enExample)
WO (1) WO2014031975A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
NZ712270A (en) * 2013-03-15 2020-02-28 Janssen Pharmaceutica Nv Pharmaceutical composition of s-ketamine hydrochloride
MX370506B (es) 2013-04-12 2019-12-16 Icahn School Med Mount Sinai Método para tratar trastorno de estrés post-traumático.
US9872841B2 (en) 2013-09-13 2018-01-23 National University Corporation Chiba University Application of R-ketamine and salt thereof as pharmaceuticals
CA2957926A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
JP6757537B2 (ja) * 2014-08-29 2020-09-23 公益財団法人ヒューマンサイエンス振興財団 神経疾患モデル動物の製造方法及び神経疾患モデル動物
AU2015318123A1 (en) 2014-09-15 2017-03-30 Janssen Pharmaceutica Nv Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression
EP3085366A1 (en) * 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
IL296380A (en) * 2015-05-22 2022-11-01 Vistagen Therapeutics Inc Therapeutic uses of l-4-chlorokynurenine
CN107847469A (zh) 2015-06-27 2018-03-27 美国神农制药责任有限公司 氯胺酮透皮递送系统
CN105249531A (zh) * 2015-08-06 2016-01-20 云南中烟工业有限责任公司 一种金丝楠木提取物的制备方法及其应用
US9884057B2 (en) * 2015-09-08 2018-02-06 The Children's Hospital Of Philadelphia Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22Q syndrome
EP3377050A4 (en) * 2015-11-17 2019-11-20 The Trustees of Columbia University in the City of New York PHARMACOLOGICAL PROPHYLACTICS AGAINST STRESS-INDUCED AFFECTIVE DISORDERS AND THEIR ASSOCIATED SYMPTOMS
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
WO2019094757A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
FR3075038B1 (fr) 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
IL319020A (en) 2017-12-22 2025-04-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
HUE058320T2 (hu) 2017-12-29 2022-07-28 Celon Pharma Sa Száraz por alakú ketamin készítmény pulmonáris adagolásra kezelésnek ellenálló depresszió esetén
BR112020016500A2 (pt) 2018-02-15 2020-12-15 National University Corporation Chiba University Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea
JP2021523228A (ja) 2018-05-04 2021-09-02 パーセプション ニューロサイエンス，インコーポレイティド 物質乱用の治療方法
WO2020041329A1 (en) * 2018-08-20 2020-02-27 Yale University Combination therapy for treating or preventing depression or other mood diseases
BR112021016404A2 (pt) 2019-02-22 2021-10-13 Harima Chemicals, Incorporated Método de aplicação de material de brasagem sólido, método de produção de peça de trabalho revestida, aparelho de aplicação e material de brasagem sólido de perfil laminado
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
EP3968977A4 (en) * 2019-05-15 2023-01-11 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS AGAINST STRESS-INDUCED MOOD DISORDERS AND THEIR ASSOCIATED SYMPTOMS
EP4364812A3 (en) * 2019-05-31 2024-09-04 Afyx Development A/S Intranasal administration of ketamine to cluster headache patients
PH12022551856A1 (en) 2020-01-22 2024-01-03 Seelos Therapeutics Inc Reducing side effects of nmda antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
AU2007229866A1 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
BRPI0809843A2 (pt) * 2007-04-26 2014-09-23 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder

Also Published As

Publication number Publication date
JP6771512B2 (ja) 2020-10-21
BR112015003796A2 (pt) 2017-07-04
IL237340A0 (en) 2015-04-30
US20250255834A1 (en) 2025-08-14
EP3878442A1 (en) 2021-09-15
JP2016501828A (ja) 2016-01-21
MX2015002378A (es) 2015-09-25
EP2887930A1 (en) 2015-07-01
US20180235906A1 (en) 2018-08-23
AU2013305580A1 (en) 2015-04-09
CN104902883A (zh) 2015-09-09
JP2018162302A (ja) 2018-10-18
EP2887930A4 (en) 2016-03-23
SG11201501292UA (en) 2015-05-28
US20140057988A1 (en) 2014-02-27
US20220160655A1 (en) 2022-05-26
WO2014031975A1 (en) 2014-02-27
JP6722453B2 (ja) 2020-07-15

Similar Documents

Publication Publication Date Title
JP6771512B2 (ja) 抗不安薬組成物、製剤および使用方法
US5543434A (en) Nasal administration of ketamine to manage pain
KR100891568B1 (ko) 나트륨 채널 차단 화합물인 테트로도톡신의 무통 제공 방법
Farah et al. Assessment of Valeriana officinalis l.(Valerian) for conscious sedation of patients during the extraction of impacted mandibular third molars: a randomized, split-mouth, double-blind, crossover study
JP2009530385A (ja) うつ病の治療のためのケタミンの鼻内投与
MD3746126T2 (ro) Metode și compoziții pentru tratamentul apneei în somn sau sforăitului simplu
KR20210125507A (ko) 수면성 무호흡의 치료 방법 및 조성물
Brent The management of pain in the emergency department
WO2001052855A2 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
US20150111852A1 (en) 1-Di(sec-butyl)-phosphinoyl-pentane (dapa-2-5) as a topical agent...
Esmat et al. Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy, a double-blind, placebo-controlled trial
US20240207338A1 (en) Ketamine and cannabis for the treatment of emotional disorders
Zingade et al. Medical Emergencies in Dentistry: A Review
RU2684563C2 (ru) Способ терапевтического лечения медикаментозного ринита, сформировавшегося на фоне приема назальных деконгестантов
Kalaivani Methamphetamine substance abuse and Dental Considerations: a modern era crisis
Tay et al. Knowing the Emergency Drugs in your Dental Practice
JP2017538777A (ja) テトラカインをベースにした麻酔剤
US9211311B2 (en) Methods for the treatment of neurodegenerative disorders
US20210015781A1 (en) Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome
Ahuja A Comparitive Clinical Evaluation of Dexmedetomidine V/S Propofol in Patients Undergoing Extraction of Impacted Mandibular Third Molars
Bolaji et al. Comparative evaluation of 0.5% ropivacaine and 0.5% bupivacaine for day case inguinal herniorrhaphy in a Nigerian Tertiary Health Institution
Bleeker Part H–Anaesthesia and Analgesia
Venter The safety and efficacy of the propofol/Alfentanil/Ketamine-bolus technique in midazolam pre-medicated patients undergoing office based plastic or reconstructive surgery
Berbrayer et al. Effects of Topical O24 Essential Oils on Patients with Fibromyalgia Syndrome: A Randomized, Placebo Controlled Pilot Study
MX2008003935A (en) Combination s-nitrosothiol-based pharmaceutical products for restoring normal breathing rhythm

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150323

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination